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ABSTRACT 
Objectives: To explore the cost-effectiveness of fluticasone propionate (FP) for the treatment of chronic 
obstructive pulmonary disease (COPD), we estimated costs and quality adjusted life years (QALYs) over 
3-years, based on an economic appraisal of a previously reported clinical trial (ISOLDE).  
Methods:  742 patients enrolled in the ISOLDE trial who received either FP or placebo had data available 
on health care costs and quality of life over the period of the study. The SF-36 based utility scores for 
quality of life were used to calculate QALYs. A combined imputation and bootstrapping procedure was 
employed in order to handle missing data and to estimate statistical uncertainty in the estimated 
cumulative costs and QALYs over the study period.   The imputation approach was based on propensity 
scoring and nesting this approach within the bootstrap ensured that multiple imputations were performed 
such that statistical estimates included imputation uncertainty. 
Results: Complete data were available on mortality within the follow up period of the study and a non 
significant trend towards improved survival of 0.06 (95% CI:-0.02 to 0.14) life years was observed.  In an 
analysis based on a propensity scoring approach to missing data we estimated the incremental costs of 
FP versus placebo to be £974 (95% confidence interval (CI): £655 to 1,344) with an additional effect of 
0.14 QALYs (CI: 0.05 to 0.24).  Cost-effectiveness estimates for the within-trial period of £15,555 per life-
year gained (£6,347 to ∞)  and £7,199 per QALY gained (CI: £3,556 to £19,540)  were generated that 
include uncertainty due to the imputation process.  An alternative imputation approach did not materially 
affect these estimates. 
Conclusions: Previous analyses of the ISOLDE study showed significant improvement on disease 
specific health status measures and a trend towards a survival advantage for treatment with FP.  This 
analysis shows that joint considerations of quality of life and survival result in a substantial increase in 
QALYs favouring treatment with FP.  Based on these data, the inhaled corticosteroid FP appears cost-
effective for the treatment of COPD.  Confirmation or refutation of this result may be achieved once the 
TOwards a Revolution in COPD Health (TORCH) study reports, a large randomized controlled trial 
powered to detect mortality changes associated with the use FP alone, or in combination with salmeterol, 
which is also collecting resource use and utility data suitable for estimating cost-effectiveness.    
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INTRODUCTION 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines chronic obstructive pulmonary 
disease (COPD) as a chronic disease characterized by non-reversible airflow limitation that is usually 
progressive and associated with an abnormal inflammatory response of the lungs to particles and gases, 
and particularly tobacco smoke (1). The symptoms of COPD, due to airway irritation and altered lung 
function, include coughing, sputum production, breathlessness, wheezing and chest pain (2). In addition 
to chronic symptoms, subjects with COPD may also experience episodes of acute exacerbations, 
commonly triggered by respiratory infection (3) that frequently require intense medical follow-up in 
hospital, sometimes including respiratory therapy (4).  The impact of COPD on health related quality of life 
is well-documented; worse health is associated with an increased likelihood of hospitalization (5), more 
frequent exacerbations (6) and increased mortality (7).  A recent study has shown that frequent 
exacerbations are associated with a more rapid decline in health status (8). 
With an approximate global prevalence of 600 million and 2.5 million deaths recorded worldwide annually, 
COPD was estimated to be the 11th leading cause of disability and the 5th leading cause of mortality in 
2000 (9). Due to ageing populations, air pollution (10) and rapid increases in the rate of cigarette smoking 
in some (mostly developing) countries (11-15) and among specific subgroups (16), it is projected that, by 
2020, COPD will become the fifth leading cause of disability and third leading cause of death in the world 
(17). 
Available treatments for moderate to severe COPD mostly comprise single agent or combination 
bronchodilator therapy (i.e. short or long acting β2-agonists, inhaled anticholinergics and theophyllines), 
and oral corticosteroids to manage COPD exacerbations (18,19).  Few long-term studies have 
investigated the effect of inhaled corticosteroids on lung function and exacerbations.  The Inhaled 
Steroids in Obstructive Lung Disease in Europe (ISOLDE) study was a randomized, placebo controlled 
clinical trial comparing inhaled fluticasone propionate (FP) versus placebo in 751 subjects with moderate 
to severe COPD (20,21).  The objective was to determine the effect of treatment on lung function, 
exacerbations and health status over the three year follow-up of the trial.  The results showed that, while 
FP did not reduce the annual rate of decline in lung function compared to placebo, significant benefits 
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were achieved in terms of reduced frequency of exacerbations and a reduction in the decline of health 
status (22,23). Because of their strong association with prolonged hospitalization and death (24), COPD 
exacerbations are often interpreted as a pertinent health outcome. In that regard, the ISOLDE study 
showed that inhaled corticosteroids could potentially yield important benefits. 
Although a main focus of the original clinical trial was deterioration of health status as measured by the 
disease-specific St George’s Respiratory Questionnaire (SGRQ) (25), the generic SF-36 health status 
measure was also included in ISOLDE (26).  The reduction in rate of health status deterioration 
associated with FP treatment occurred over all domains of the SGRQ and the Physical Function, Physical 
Role, Energy/Vitality and Mental Health domains of the SF-36 (27).  The recent publication of an 
algorithm to translate SF-36 scores into utility scores (28) offers, for the first time, the potential for the 
improvement in health status associated with treatment already observed in ISOLDE to be translated into 
a gain in Quality Adjusted Life Years (QALYs).  QALYs explicitly combine length and quality of life in a 
single measure and are the preferred metric in health economic evaluations for bodies such as the 
National Institute for Clinical Excellence (NICE) in the UK (29), as they allow the direct comparison of 
treatment cost-effectiveness between disease areas.    
 
METHODS 
Following the early withdrawal of nine patients prior to double-blind randomization in the ISOLDE trial, 
742 patients were available for analysis.  The economic analysis was conducted from a UK public sector 
(Health and Personal Social Services) perspective over the three years of the clinical study. Costs and 
effects were discounted at the rate of 3.5% per annum, the rate currently recommended in the most 
recent guidance from NICE in the UK (29). 
 
Calculation of utility scores 
In the ISOLDE study, the generic SF-36 instrument was administered every six months for the three years 
of follow-up, generating a maximum of six possible observations for patients enrolled in the trial.  Brazier 
and colleagues have reported work on deriving a reduced health status index from the SF-36 that they 
term the SF-6D (30) and more recently, they have published an algorithm that allows the estimation of 
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utility scores for all states of the SF-6D index (31).  Following this published algorithm, the SF-36 scores 
observed in the trial were converted to utility scores.  Accumulating these scores over the maximum of six 
visits (three years) of the study allowed the estimation of per patient QALYs for ISOLDE. 
 
Estimation of costs 
In addition to the cost of treatment, six categories of resource were collected as part of ISOLDE: rescue 
medication use; concomitant medication use; visits to the general practitioner; visits to outpatient clinics; 
visits to the emergency room and inpatient hospital stays.  Unit costs for medications were obtained from 
the British National Formulary (32), and the unit costs of health service contacts from a published 
compendium of unit cost figures (33).  For the purposes of this analysis, costs were accrued for the same 
six month periods relating to the visits at which health status was measured.  Accumulating these costs 
over the maximum six periods (three years) gave the per-patient total cost for the study. The costing 
employs a base year of 1998-99, corresponding to the year in which trial ended.   
 
Missing data due to attrition 
One important issue observed in the ISOLDE clinical trial was the high rate of withdrawals over the three 
years of follow-up.  Experiencing COPD-related adverse events was also stated as one of the main 
reasons for dropping out and the overall rate of dropout was higher in the placebo group at 53% of 
subjects compared to 43% in the FP group (34). Consequently, a large amount of data on periodic costs 
and utilities had missing values over the three years of the clinical study.  Although the original clinical 
study reported 36 deaths during the study period in the placebo group compared to 32 among those 
allocated to FP, these represented only deaths prior to dropout from the study.  Retrospective 
examination of death records revealed that there were in fact 58 deaths among those allocated placebo 
within the three year period of the study compared to just 45 in the FP arm of the study.  Having adjusted 
for data known to be unavailable due to death, the rate of missing data observations was estimated to be 
20% for costs and 34% for SF-36 information at scheduled visit dates (see Table 1). 
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A preliminary analysis of QALYs and cost was conducted based only on the complete cases for each 
category of data (complete information was available for the life-year analysis as described above).  This 
provides a useful reference point for comparison with the full imputation analysis described below.  When 
combining complete cases of cost and QALYs (and life years) to estimate cost-effectiveness the full set of 
complete case information was retained, however, covariance information for confidence interval 
calculation could only be estimated from patients that had both cost and effect information available. 
 
Imputation of missing information  
For cost and utility information that was missing after dropout from the study but before death/end of the 
three year follow-up period the values of the missing observations were imputed.  Following Oostenbrink 
and colleagues (35), an imputation approach based on propensity scoring was employed with baseline 
variables including age, smoking status, gender, pulmonary function (forced expiratory volume in one 
second), body mass index categories and disease-specific SGRQ score entered into a logistic regression 
to predict the chance of a missing value.  In addition, one-period lagged values of the relevant cost or 
utility score were included as explanatory variables.  The predicted probability from this regression is the 
propensity score and on the basis of this predicted probability, the available data were arranged into 
quintiles.  Where cost data or a utility score were missing, a replacement value was selected at random 
from the available data points within the same quintile.  By choosing a value at random within the same 
quintile the principle of multiple imputation could be employed (36).  Multiple imputation procedures are 
considered more valid than single imputation methods because instead of filling in a single value and 
treating it as known (as would be the case if a single value based on the closest propensity match was 
used), in each imputation uncertainty in the imputation process is taken into account such that the 
imputed data points represent a random sample of the missing values (37).   
 
Although the standard approach is to use a small number of imputed datasets in a multiple imputation 
process, the recent ISPOR Task Force on CEA alongside clinical trials suggested that both statistical and 
imputation uncertainty could be combined by bootstrapping the whole imputation/estimation process (38).  
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Therefore, the existing data set was first bootstrapped including the missing data and then the imputation 
process was employed to fill in the missing values.  The whole bootstrap/imputation procedure was then 
repeated 1,000 times in order to generate an overall estimate of uncertainty that includes uncertainty in 
the imputation process.   
 
In a more qualitative sensitivity analysis of the imputation procedure a best and worst case analysis was 
also performed.  For the best case, imputed values for the costs and utilities in the FP group were based 
on the mean cost and utility in the first period for all completers, and for the placebo group the mean cost 
and utility in the last available period for subjects that eventually dropped out (when costs were generally 
higher and utilities lower). For the worst case scenario, we applied the reverse logic by imputing values 
for FP that were based on mean cost and utility for the last period prior to subjects dropping out and for 
the placebo group we used the mean costs and utility in the first period for all completers.   These 
alternative imputation approaches allowed the importance of the chosen imputation method to be 
assessed. 
 
Economic Analysis 
The three outcomes estimated for the economic analysis were cumulative costs, life expectancy and 
quality-adjusted life expectancy over three years. To determine cost-effectiveness, we calculated the 
incremental cost-effectiveness ratio (ICER) as the ratio of the difference in costs between FP and placebo 
to the difference in effects.  Lower values of the ratio suggest that the benefits of treatment come at lower 
cost and therefore indicate better value for money.  Feiller’s theorem (39,40) was employed to generate 
confidence intervals for cost-effectiveness estimates based on complete data, whereas the non 
parametric bootstrap was used to represent the combination of statistical/imputation uncertainty where 
multiple imputation was employed.  Uncertainty surrounding the ICER was also presented on the cost-
effectiveness plane (41,42).   
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RESULTS 
The mortality curves for FP and placebo are presented in Figure 1. The difference in survival was 
estimated to be 23 days or 0.06 life years over the study period, although this difference did not reach 
statistical significance at conventional levels (p=0.11).  No imputation was necessary for mortality as the 
data were complete.  The extent of missing information relating to cost and utility is summarized in Table 
1 and shows that approximately 20% of the observations relating to cost and 34% of the observations 
relating to utility were missing.  Furthermore, data were more likely to be missing from the placebo than 
the treatment group.  These missing observations have a more profound effect on complete cases with 
just 69% of patients having a complete set of cost data and only 41% of patients having complete 
information on utilities. 
 
A complete case analysis based only on those patients that had full and complete data for the three year 
follow-up of the study is reported in Table 2, with all confidence intervals calculated using standard 
parametric methods.  These results show that FP is associated with a significantly increased cost, but 
also a significant benefit in terms of QALYs gained over the three year study period.  These results are 
presented on the cost-effectiveness plane in terms of both life-years and QALYs gained in Figure 2.  
Despite these promising results there are two concerns with the complete case analysis presented in 
Table 2 and Figure 2.  Firstly, the reduced sample size as a basis for this analysis is wasteful of 
information (due to excluding patients with some information, but who are missing at least one data point) 
with consequent loss of power.  Secondly, the results may be biased if the data are not missing 
completely at random. 
 
The imputation results for the propensity scoring method are reported in Table 3 and Figure 3 where 
confidence intervals are now calculated non-parametrically and include both sampling and imputation 
uncertainty by nesting the imputation within the bootstrap.  The incremental costs of FP versus placebo 
was estimated to be £974 (95% confidence interval: £655 to 1,344) with an additional effect of 0.14 
QALYs (0.05 to 0.24).  Cost-effectiveness for the within-trial period was estimated to be £15,555 per life-
year gained (£6,347 to ∞)  and £7,199 per QALY gained (£3,556 to £19,540).  The results of the 
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sensitivity analysis for the best case scenario resulted in an ICER point estimate of £5,170 while the worst 
case scenario yielded an ICER of £13,220.   
 
The confidence ellipses of Figure 2 based on complete case analysis are overlaid in Figure 3 and show 
how the imputation approach changes the location of the joint distribution slightly, but that the main effect 
is to reduce the variance of the estimates, particularly for QALYs gained where missing data observations 
were greatest. 
 
DISCUSSION 
In this study, we have estimated the cost-effectiveness of fluticasone propionate versus placebo using 
data from the previously published ISOLDE study.  It is only following the publication of an algorithm for 
converting data on the SF-36 instrument to utility scores suitable for calculating QALYs that it has been 
possible to directly estimate cost-utility results from ISOLDE.   ISOLDE was not designed to have 
sufficient power to detect differences between groups for mortality, but nevertheless showed a trend 
towards reduced mortality.  The results of the analysis reported here show that combining that trend with 
the significant improvement previously reported in health status resulted in a highly significant QALY gain.  
However, given the retrospective nature of the analysis and the fact that the study was not powered for 
mortality differences, these results should be considered as hypothesis generating. 
 
The high rate of withdrawal in the clinical study required the use of imputation techniques to handle 
missing data.  Of particular concern was that there was a strong indication that the attrition was related to 
adverse outcomes with those experiencing COPD-related adverse events representing the majority of 
patients dropping out of the study. This means that the underlying pattern of missingness was certainly 
not completely at random and may be informative. Informative missingness is problematic in that any use 
of statistical techniques based on observed data are potentially misleading, while modeling unobserved 
data requires assumptions that are difficult to verify. Our solution was to use propensity scoring as the 
base case analysis, since this at least imputes from the group of patients that had a similar propensity to 
have missing values and might, therefore, account for some of the informative nature of those missing 
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values.  In addition, a more qualitative analysis of replacing missing values examined ‘best case’ and 
‘worst case’ scenarios (from the perspective of the intervention under study) and revealed that even if 
missing values were deliberately stacked against the intervention, the estimate of cost-effectiveness was 
still within acceptable limits.  That the estimated cost-effectiveness was insensitive to the choice of 
imputation method used (even under extreme assumptions) suggests that the level of missingness in 
ISOLDE does not invalidate the results. 
 
The original costing of ISOLDE was undertaken using a cost base year corresponding to the year that the 
trial closed.  While this may seem to be out of date for a current analysis, we have not attempted to 
update the costing for two main reasons.  First, for some resource use categories (such as concomitant 
medications) the individual resource use quantities are not available, and so any updating of costs could 
only be achieved through the use of a health service inflation index.  Secondly, the price of FP has not 
changed since the trial was undertaken.  Therefore, the analysis presented here is conservative, since 
the cost of FP is effectively the current price, while any cost-savings from the reduction in other health 
service resource use associated with treatment are currently valued using 1998/99 unit costs. 
 
The results of this study suggest that inhaled fluticasone propionate is associated with increased quality-
adjusted survival when compared with placebo. This adds support to the need to account for the quality-
of-life considerations when evaluating treatments for COPD. These benefits came at relatively small 
overall incremental costs resulting in a favourable cost-effectiveness ratio for FP compared to placebo.  
For example, while NICE have strenuously denied the existence of a single cost-per-QALY threshold, 
they have indicated that they would be unlikely to reject a treatment in the range of £5,000-15000 per 
QALY purely on cost-effectiveness grounds (43). The effect of inhaled corticosteroids alone or in 
combination with a long acting beta-agonist on survival is currently being investigated in TORCH 
(TOwards a Revolution in COPD Health), a large randomized controlled trial involving over 6,000 patients 
comparing the effects of FP alone, or in combination with salmeterol, with placebo (44).   This study 
should provide further evidence on the effectiveness and cost-effectiveness of inhaled corticosteroids 
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alone and in combination and could provide the definitive analysis to confirm or refute the ISOLDE results 
presented here.  
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Table 1 
Missing data observations and implications for complete cases 
Placebo FP Placebo FP
(n=370) (n=372) (n=370) (n=372)
Total observations 2,077 2,129 2,077 2,129
Of which complete 1,314 1,482 1,616 1,749
% observations missing 37% 30% 22% 19%
Total cases complete 135 168 242 269
% cases missing 64% 55% 35% 28%
SF index Total Costs
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Table 2 
Cost effectiveness analysis based only on complete cases 
Placebo ( 95% CI) FP ( Difference (
Life Years 2.75 ( 2.68 - 2.81 ) 2.81 ( 2.76 - 2.86 ) 0.06 ( -0.02 - 0.14 )
QALYs 1.68 ( 1.56 - 1.79 ) 1.85 ( 1.76 - 1.95 ) 0.18 ( 0.03 - 0.32 )
Cost £1,341 ( - ) £2,494 ( - ) £1,153 ( £813 - )
Cost per life year
Undiscounted £18,413 ( - ∞ )
Discounted £20,037 ( - ∞ )
Cost per QALY
Undiscounted £6,471 ( - )
Discounted £6,553 ( - )
£1,084
£3,321
£35,051
£8,495
£1,597 £1,493£2,271 £2,717
95% CI) 95% CI)
£35,571
£3,284
£7,804
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Table 3 
Cost-effectiveness analysis based on full imputation 
Placebo ( 95% CI) FP ( Difference (
Life Years 2.74 ( 2.68 - 2.80 ) 2.81 ( 2.76 - 2.85 ) 0.06 ( -0.02 - 0.14 )
QALYs 1.71 ( 1.64 - 1.77 ) 1.84 ( 1.79 - 1.92 ) 0.14 ( 0.05 - 0.24 )
Cost £1,526 ( - ) £2,500 ( - ) £974 ( £655 - )
Cost per life year
Undiscounted £15,555 ( - ∞ )
Discounted £17,065 ( - )
Cost per QALY
Undiscounted £7,199 ( - )
Discounted £7,237 ( - )
£1,276
£3,595
£19,540
£7,847
£1,823 £1,344£2,335 £2,749
£3,896,792
95% CI) 95% CI)
£18,933
£3,556
£6,347
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Figure 1 
Failure curves for time to death in the Placebo and FP arms 
Separation shown is non significant (p=0.11) 
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Figure 2 
Complete case cost-effectiveness on the cost-effectiveness plane: left panel shows cost per life year; right panel shows cost per QALY 
I-Bars show 95% confidence intervals for incremental cost and effect crossing at the point estimates; joint distribution of incremental cost and 
effect  is shown using 5%, 50% and 95% confidence ellipses 
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Figure 3 
Full imputed cost-effectiveness analysis on the CE plane: left panel shows cost per life-year; right panel shows cost per QALY 
Imputed results are shown by the bootstrap joint densities; ellipses based on complete case analysis of Figure 2 overlaid for comparison 
